COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Serenity Mental Health Centers, a leader in innovative psychiatric care and one of the fastest-growing mental health providers in the nation, today announced the expansion of its ketamine infusion therapy services in Colorado Springs. Serenity’s board-certified psychiatrists and psychiatric mental health nurse practitioners provide full-spectrum mental health services tailored to each patient’s needs. Ketamine is provided when the provider determines tha

Novel SA53 MDM2 Inhibitor Therapy Has Potential to be a Breakthrough in Genetically-Targeted Cancer Treatment CLEVELAND, OHIO, UNITED STATES, November 3, 2025 / EINPresswire.com / -- Lamassu Biotech , a clinical-stage pharmaceutical company, today announced a significant clinical milestone in its Phase 1/2a trial investigating SA53, a first-in-class, small-molecule MDM2 inhibitor. According to data reviewed to date, there have been no serious or dose limiting adverse events, and SA53 has thus fa

NEW YORK, Nov. 3, 2025 /PRNewswire/ -- Canopy, the leader in Enterprise AI for oncology, today announced a partnership with Willamette Valley Cancer Institute and Research Center (WVCI), a leader in advanced cancer treatments for over 25 years, to improve care between visits for both patients and staff. "We continuously evaluate technology solutions to help us provide better care for our patients while lowering the administrative burden for our staff," said Casey Chiasson, MBA, Executive Directo

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a late-stage clinical biotechnology company developing potential first-in-class immunotherapies for the benefit of people living with debilitating and progressive rare autoimmune diseases and cancers, today announced that the Company will present interim data from the Phase 1/2 clinical trial evaluating the safety, tolerability, and hematological effect of ulviprubart in patients with T cell large granular lymphocytic leukemia (T-LGLL) who suffer fro

First study to demonstrate that interventions to help quit vaping nicotine can simultaneously reduce cannabis use among adolescents and young adults WASHINGTON, Nov. 3, 2025 /PRNewswire/ -- A new study published in Substance Abuse Treatment, Prevention, and Policy today from Truth Initiative — the nation's largest public health nonprofit dedicated to preventing youth and young adult nicotine addiction and empowering quitting for all — reveals that its text message vaping cessation program not o

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual Meeting, to be held December 6 – 9, 2025, in Orlando. "This year’s Incyte presentations highlight the potential of our portfolio to transform the treatment of blood cancers, specifically for patients with myeloproliferative neoplasms (MPNs),” said Pablo J. Cagnoni, M

$100 million multi-stage prize competition to develop innovative broad-spectrum antiviral therapies CAMBRIDGE, Mass., Nov. 3, 2025 /PRNewswire/ -- Start2 Group, Inc., a global leader in startup de-risking and acceleration, today announces its partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), to launch a new prize

MAPLE GROVE, Minn., Nov. 3, 2025 /PRNewswire/ -- Peli BioThermal, the global leader in temperature-controlled packaging solutions, today announced that its newly expanded Allentown, Pennsylvania Service Center is officially open for business. The upgraded facility strengthens the company's Global Services Network, supporting increased customer demand, new product offerings, and continued innovation in the pharmaceutical cold chain industry. The Allentown Service Center has relocated to a larger,

Company is Well Positioned to Continue to Compete and GrowMARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the CY 2026 Physician Fee Schedule (“PFS”) final rule, which was published on Friday. “Over the last several years, we have actively engaged with numerous stakeholders to advocate for much-needed reform of the Medicare reimbursement system for

Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHLPreclinical data demonstrated that combining eti-cel with low-dose IL-2 may deepen and extend anti-tumor activity in patients with r/r NHLEti-cel full Phase 1 dataset, including low-dose IL-2 combination cohorts, expected to be presented in 2026Correlation between alemtuzumab exposure and response with lasme-cel (UCART22) allows optimization